Evotec narrows Q3 EBITDA loss to €1.6 million
Key points
- Evotec (NASDAQ:EVO) reported third-quarter 2026 revenue of €164.9 million, broadly unchanged from €163.9 million a year earlier, while adjusted EBITDA loss narrowed to €1.6 million.
- Revenue declined 13.1% to €465.0 million, while adjusted EBITDA loss widened to €44.3 million from €16.9 million.
- Evotec maintained its 2026 revenue guidance of €570 million–€610 million and outlined a 2030 revenue target of approximately €1 billion.
Evotec (NASDAQ:EVO) reported third-quarter 2026 revenue of €164.9 million, compared with €163.9 million a year earlier, while its adjusted EBITDA loss narrowed to €1.6 million from €15 million.
For the first nine months of 2026, revenue declined 13.1% to €465 million from €535.1 million, while adjusted EBITDA deteriorated to a loss of €44.3 million from €16.9 million.
The company reaffirmed its 2026 revenue guidance of €570 million–€610 million and adjusted EBITDA loss forecast of €70 million–€105 million, while reporting €400.9 million in quarter-end liquidity and more than 20% progress toward its €75 million annual Horizon savings target.
The company operates through Discovery and Preclinical Development and Just – Evotec Biologics, providing drug discovery, research, development and biologics manufacturing services to pharmaceutical and biotechnology partners.
Evotec's longer-term framework targets approximately €1 billion in revenue by 2030, an adjusted EBITDA margin of 20% by the end of 2028 and more than 20% by the end of 2030.
Its strategic review also remains ongoing.
Frequently asked questions
More from United States
Grand Canyon Education Q3 net income jumps to $43M
Beyond Meat posts $64.5 million in third-quarter revenue
NorthWestern Energy maintains 2026 earnings guidance
Fortuna Mining generates $90.8 million Q3 free cash flow
ArcelorMittal posts $391 million Q3 loss after Ukraine shutdown
Vicore Pharma reports SEK 133.3 million Q3 operating loss
